Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
HPG-MTX
- Development stage
- Preclinical
- Modality
- Small Molecules, Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Administration
- Intravenous, Subcutaneous, Intramuscular, Oral, Intrathecal
01
Overview
HPG-MTX is a nanoparticle-based formulation in which methotrexate (MTX), a well-known antimetabolite and immunosuppressant, is chemically conjugated to hyperbranched polyglycerol (HPG). This drug is designed to improve methotrexate delivery, enhance pharmacokinetics, and reduce toxicity. The mechanism of action derives from methotrexate's properties: it inhibits dihydrofolate reductase, blocking tetrahydrofolate synthesis, which is crucial for DNA and RNA synthesis, thus exerting cytotoxic effects in cancer and immunomodulatory effects in autoimmune disease. Conjugation to HPG exploits the physicochemical properties of nanoparticles to increase bioavailability and stability while aiming to mitigate MTX’s adverse effects seen with free drug formulations. The primary indication for HPG-MTX is presumed to be investigational uses in cancer or autoimmune diseases, leveraging the established mechanism of action of methotrexate in a novel delivery system[1][2].
- Other names
- HPG-MTX
02
Targets
TS (Thymidylate synthase)DHFR (Dihydrofolate reductase)
Beyond the preview
Go deeper on HPG-MTX.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on HPG-MTX.